|Bid||58.11 x 0|
|Ask||58.46 x 0|
|Day's range||57.93 - 58.32|
|52-week range||46.22 - 61.15|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Dr. Anand Swaminathan, Emergency Medicine Physician in New Jersey, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
Gilead (GILD) delivered earnings and revenue surprises of 6.25% and 1.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
(Reuters) -Gilead Sciences Inc on Thursday posted a higher-than-expected second-quarter profit, helped by strong demand for its COVID-19 antiviral treatment, Veklury, but sales of its flagship HIV drugs lagged as the pandemic continued to limit visits to doctors. Sales of HIV medicines, which have stalled during the coronavirus pandemic, fell 2% to $3.9 billion. Gilead Chief Commercial Officer Johanna Mercier on a conference call with analysts said HIV sales in Europe have begun to recover, but U.S. demand has been slower.